5244702025-01-012025-03-315244702025-03-315244702024-03-315244702024-04-012025-03-315244702025-01-012025-03-31in-capmkt:OtherExpenses1Member5244702024-04-012025-03-31in-capmkt:OtherExpenses1Member5244702025-01-012025-03-31in-capmkt:ReportableSegments1Member5244702025-01-012025-03-31in-capmkt:ReportableSegments2Member5244702025-01-012025-03-31in-capmkt:ReportableSegments3Member5244702024-04-012025-03-31in-capmkt:ReportableSegments1Member5244702024-04-012025-03-31in-capmkt:ReportableSegments2Member5244702024-04-012025-03-31in-capmkt:ReportableSegments3Member5244702025-01-012025-03-31in-capmkt:ReportableSegments1Member5244702025-01-012025-03-31in-capmkt:ReportableSegments2Member5244702025-01-012025-03-31in-capmkt:ReportableSegments3Member5244702024-04-012025-03-31in-capmkt:ReportableSegments1Member5244702024-04-012025-03-31in-capmkt:ReportableSegments2Member5244702024-04-012025-03-31in-capmkt:ReportableSegments3Member5244702025-01-012025-03-31in-capmkt:ReportableSegments1Member5244702025-03-31in-capmkt:ReportableSegments1Member5244702025-01-012025-03-31in-capmkt:ReportableSegments2Member5244702025-03-31in-capmkt:ReportableSegments2Member5244702025-01-012025-03-31in-capmkt:ReportableSegments3Member5244702025-03-31in-capmkt:ReportableSegments3Member5244702025-01-012025-03-31in-capmkt:ReportableSegments1Member5244702025-03-31in-capmkt:ReportableSegments1Member5244702025-01-012025-03-31in-capmkt:ReportableSegments2Member5244702025-03-31in-capmkt:ReportableSegments2Member5244702025-01-012025-03-31in-capmkt:ReportableSegments3Member5244702025-03-31in-capmkt:ReportableSegments3Member5244702025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15244702024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15244702025-01-012025-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares524470SYNCOMFNOTLISTEDINE312C01025SYNCOM FORMULATIONS (INDIA) LIMITEDMain BoardEquity2024-04-012025-03-312025-05-192025-05-13INRLakhsQuarterlyFourth quarterMulti segment2025-05-1916:00:002025-05-1917:45:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated14887640006942800015581920008016050001579280004412100014974700011680001286400015784000013252730002329190008200023300100046000000100580005605800001769430000000176943000-22819000154124000000094000000010.160.16000.160.160002024-04-012025-03-31AuditedConsolidated465012600017434000048244660002780293000399675000-10661500052173700086490005193900051371900041693970006550690005800065512700014744300013338000160781000049434600000004943460004580200054014800000000024590380000.570.57000.570.57000OTHER EXPENSES157840000OTHER EXPENSES513719000775261000047334400004720000003618200000139714000175896000081580001433131000413320000892164000107548500071200000543530003532200020644440000221912000269967600000413280700094000000024815760003421576000034215760000000133350001333500041684000631050000011812400045836000228133000199841000427974000213000004951100005616200041835000005931070007112310004132807000Pharmaceuticals Drugs & Formulations1525954000Trading of Commodities21345000Renting of Property10893000Pharmaceuticals Drugs & Formulations4702733000Trading of Commodities82584000Renting of Property39149000155819200048244660000015581920004824466000Pharmaceuticals Drugs & Formulations223706000Trading of Commodities419000Renting of Property10044000Pharmaceuticals Drugs & Formulations625862000Trading of Commodities2035000Renting of Property358790002341690006637760001168000864900000233001000655127000Pharmaceuticals Drugs & Formulations3611142000Trading of Commodities44867000Renting of Property476798000413280700004132807000Pharmaceuticals Drugs & Formulations688849000Trading of Commodities8276000Renting of Property141040007112290000711229000Notes <BR> The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 19052025 <BR> These above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind ASas notified prescribed under Section 133 of the Companies Act 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to time. <BR> The company is operating in 3 segments ie Pharmaceuticals Drugs Formulations b Trading of Commodities c Renting of Property particulars of segment wise results are given as required. <BR> The Standalone Statement of Assets and Liabilities as at 31st March 2025 and the Standalone Statement of Cash Flow is provided as an annexure to this statement. <BR> As required under Regulation 33 of SEBI LODR Regulations 2015 the Auditors report provided by the Statutory Auditors have carried out Audit books of Accounts for the Financial year 2024 2025 and issued us an Audit Report with an unmodified opinion on Audited financial Results for the Quarter Year ended 31st March 2025 Therefor the company is not required to give statement of Impact of Audit Qualification for Audit report with modified opinion <BR> Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification <BR> The figures of the Last Quarter are the balancing figures between the audited figures in respect of full financial year & the published year to date figures upto 3rd quarter of that financial year <BR> The Company has three Wholly Owned Subsidiaries namely Synmer Pharma Private Limited, Vincit Biotech International Private Limited, Sante Biotech Private Limited8649000-202505000-425010000-11163500000-115750000186535000014892000048025000055260000-6200000000000-16867200000-2733230003818040000001474430000234361000000000000995930000217767000000000000000000000135318000-18204200000000000-679030000000864900008646000-679033000-6267140000-626714000633834000712000000Items that will be reclassified to profit and loss account-22819000-22819000Items that will be reclassified to profit and loss account458020004580200000-2281900045802000AuditedtrueSanjay Mehta And Associates, Chartered Accountantstrue2027-03-31